Translational Oncology Research Laboratory
2019 Translational Oncology group. L-R: 1st row - Dr Ashalyn Watt, Dr Sophia Frentzas, Prof Eva Segelov, Dr Sameer Greenall. 2nd row - Mr Timothy Chen, Dr Gwo Yaw Ho, Dr Edmond Kwan, Ms Annette McClellan
Unfortunately some cancer patients don’t respond or are resistant to therapy. Our research aims to find out why.
Focussing on the upper and lower gastrointestinal cancers, colorectal cancer, lung cancer and brain cancer, our laboratory seeks to understand how patient tumours respond to clinical therapies (such as immunotherapy, targeted therapy and chemotherapy), why patient tumours are able to resist clinical therapy, and discover biomarkers of response. Our ultimate goal is to use this new knowledge to improve clinical practise, more effectively treat patients and improve their survival and wellbeing.
Immunotherapy, ctDNA, Genomic adaptation, Immunological adaptation and response, Neoadjuvant therapies, Tumour immunogenicity
Meet the Translational Oncology Research Laboratory team.
See Pubmed link for recent publications.
- Clinical Genomics
- Australasian Gastro-Intestinal Trials Group (AGITG)
- Aspirin for Dukes C and High Risk Dukes B Colorectal Tumours (ASCOLT) Trial Group
Current Clinical Trials
- NCT00565708: Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers (ASCOLT) Trial. In this randomized, placebo-controlled adjuvant study, investigators will see if Aspirin in patients with dukes C or high risk dukes B colorectal cancer (ASCOLT) can improve survival in this patient population over placebo control.
- NCT03084770: Asymptomatic Small Pancreatic Endocrine Neoplasms (ASPEN) Trial. The aim of the study is to evaluate the most appropriate management of sporadic asymptomatic non-functioning pancreatic neuroendocrine neoplasms (NF-PNEN) ≤ 2 cm
- Rectal AveRec Neo Adjuvant Rectal ES FM
- Solid Tumour KX-012AX-002 Bioequivalence study of oral paclitaxel in patients treated with IV paclitaxel ES IN
- HREC/18/MonH/346: The role of dendritic cells (DCs) in non-small-cell lung carcinoma (NSCLC) patients receiving anti-PD-1 immunotherapy. This study will take sequential blood and tumour biopsies to monitor immunological tumour responses to immunotherapy.